Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
(NASDAQ: ERNA) Delayed: 3.76 -0.15 (3.84%)
Previous Close $3.91    52 Week High $ 
Open $4.04    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.71    EPS $ 
Volume 33,601       

(NASDAQ: ERNA) Delayed: 3.76 -0.15 (3.84%)
Previous Close $3.91    52 Week High $ 
Open $4.04    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.71    EPS $ 
Volume 33,601